Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab 200 mg subcutaneous injection local tolerability crossover study in healthy volunteers
NL-OMON49835Phase 1Completed
- Sponsor
- Almirall
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risankizumab in psoriasis (2 arms), sponsored by Almirall. Primary endpoint: Local tolerability. Started Sep 2020; status: completed.
02
Drugs
risankizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON49835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49835.